Allogenic stem cells (Celavie Biosciences)(Allogenic stem cells (Celavie Biosciences))

概要

基本信息

药物类型

神经干细胞疗法

别名

Human neural progenitor cell Celavie Biosciences、OK99 undifferentiated stem cells、hNPCs Celavie Biosciences

+ [1]

靶点-

作用机制

干细胞替代物

治疗领域

神经系统疾病

在研适应症

癫痫

非在研适应症

小脑共济失调帕金森病

原研机构

Celavie Biosciences LLC

在研机构

The California State University

Celavie Biosciences LLC

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 Allogenic stem cells (Celavie Biosciences) 相关的临床试验

NL-OMON49611 / RecruitingN/AIIT

Systemic inflammation in ALSP patients and the effect of an allogenic hematopoietic stem cell transplantation on the inflammation - Systemic inflammation in ALSP patients

开始日期2021-02-03

申办/合作机构-

NCT02780895 / Unknown status临床1期

Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease

Implantation of Celavie human stem cells (OK99) is intended to address the underlying pathology of the disease by replacing damaged/destroyed cells of the brain, and/or stimulating the patient's brain to repair itself.

开始日期2014-05-01

申办/合作机构

Celavie Bioscences, LLC

100 项与 Allogenic stem cells (Celavie Biosciences) 相关的临床结果

登录后查看更多信息

100 项与 Allogenic stem cells (Celavie Biosciences) 相关的转化医学

登录后查看更多信息

100 项与 Allogenic stem cells (Celavie Biosciences) 相关的专利（医药）

登录后查看更多信息

3

项与 Allogenic stem cells (Celavie Biosciences) 相关的文献（医药）

2021-01-02·Human Vaccines & Immunotherapeutics3区 · 医学

Allogenic mouse cell vaccine inhibits lung cancer progression by inhibiting angiogenesis

3区 · 医学

Article

作者: Lu, Jing ; Zhou, Lurong ; Zhang, Xiaoling ; Zhao, Jun ; Du, Yunyi ; Zhao, Jimin ; Dong, Ziming

Aim: This research investigated the therapeutic effect of an allogeneic mouse brain microvascular endothelial cell vaccine on lung cancer and further elucidated its potential anti-angiogenic mechanism. Materials & methods: The immune effect of the allogeneic bEnd.3 vaccine and DC vaccine loaded with bEnd.3 antigen on the subcutaneous transplantation of Lewis lung cancer (LLC) was assessed by ELISA, the CCK test and the CTL killing test. The mechanism was preliminarily revealed by immunohistochemistry and immunoblot analysis. Results: This study revealed that tumor volume was decreased (p < .01) and the survival was prolonged significantly (p < .05) by the bEnd.3 vaccine in subcutaneous LLC transplantation in the vaccine prevention group. In contrast, both tumor volume in the serum therapeutic group and survival of bEnd.3 vaccine were not significantly different from those of the control group (p > .05). Importantly, tumor volume and survival of the T lymphocyte therapeutic group were decreased and prolonged (p < .05). In addition, both tumor volume and survival of DC vaccine loaded with bEnd.3 in the vaccine prevention group were decreased and prolonged significantly (p < .01). Furthermore, bEnd.3 vaccine and DC vaccine loaded with bEnd.3 both produced the activity of killing bEnd.3 target cells in vitro.The reason may induce the immune mice to produce anti-VEGFR-II, anti-endoglin and anti-integrin αν antibodies to have an anti-angiogenesis function. Conclusion: The allogeneic mouse bEnd.3 cell vaccine can block angiogenesis and prevent the development of lung cancer transplantation tumors.

2015-11-01·Annals of Oncology1区 · 医学

Why has active immunotherapy not worked in lung cancer?

1区 · 医学

Review

作者: Giaccone, G ; Thomas, A

Vaccines that rely on active specific stimulation of the host immune system have the potential to trigger durable antitumor responses with minimal toxicity. However, in nonsmall-cell lung cancer (NSCLC), several large phase III trials of vaccines reported within the last year have yielded disappointing results. Compared with placebo, belagenpumatucel-L (an allogenic tumor cell vaccine), tecemotide (a peptide vaccine targeting MUC-1) and melanoma-associated antigen-A3 (a protein-based vaccine) did not improve outcomes in NSCLC. The lack of clinically significant outcomes, despite their ability to prime and expand tumor antigen-specific T cells could at least partly be attributed to the inability of vaccine-induced T-cell responses to overcome the tumoral mechanisms of immune escape which limit the clonal expansion of T cells following vaccination. A number of such mechanisms have been recognized including reduced antigen presentation, antigenic loss, cytokines, immunosuppressive cells and immune checkpoints. Strategies aimed at modulating the immune checkpoints have shown promise and are on the verge of revolutionizing the therapeutic landscape of metastatic NSCLC. Overcoming immune tolerance and improving the activation of antitumor T cells via combinatorial approaches may represent a new and more promising therapeutic application for active immunotherapies in NSCLC.

2006-01-01·Immunopharmacology and Immunotoxicology4区 · 医学

Triggering of T Cell-Mediated Immune Responses by Allogenic Tumor Cell Vaccine in Patients with Oral Cancer

4区 · 医学

Article

作者: Satish K. Devarapu ; Suresh C. Sharma ; Satya N. Das

We investigated the immunomodulatory activity of allogenic whole tumor cell vaccine in oral cancer patients in vitro by two-color flow cytometry. Vaccine treatment significantly increased the expression of CD69 and HLA-DR in CD3+ T-cell subsets. The frequency of Interferon-gamma and Interleukin (IL)-2 expressing CD4+/CD8+ T-cell subsets was significantly higher with a concomitant reduction in IL-4 and IL-10 expressing T-cells in the vaccine treated group as compared with the untreated controls. Vaccine treatment significantly increased T-cell receptor (TCR), Vbeta3, Vbeta5 and Vbeta8 usage. The results indicate that the allogenic whole tumor cell vaccine is able to trigger T-cell mediated immunity in patients with intraoral squamous cell carcinoma.

100 项与 Allogenic stem cells (Celavie Biosciences) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
小脑共济失调	临床1期	美国	Celavie Biosciences LLC	-
癫痫	临床前	美国	The California State University	-
癫痫	临床前	美国	Celavie Biosciences LLC	-
帕金森病	药物发现	墨西哥	Celavie Biosciences LLC	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EHA2017	N/A	慢性淋巴细胞白血病	11	Ibrutinib	(壓簾鹹齋壓鏇淵鬱蓋壓) = 窪繭鹽襯艱壓艱憲衊夢遞壓壓遞廠鬱醖網夢獵 (衊壓淵襯顧淵製範遞鹽 )	-	2017-05-18
				Non-myeoloablative allogenic stem cell transplantation	(艱壓獵襯齋廠窪蓋鏇艱) = 艱壓製艱壓窪顧淵鑰鹹築壓醖衊積願簾襯網夢 (選淵願願遞鑰膚夢願餘 ) 更多